Endocrine impact of transfusion therapy: parathyroid status in pediatric thalassemia major

Authors

  • Audity Titas Department of Paediatrics and Neonatology, United Hospital Limited, Dhaka, Bangladesh
  • A. K. M Amirul Morshed Khasru Department of Paediatric and Oncology, Dhaka Medical College Hospital, Dhaka, Bangladesh
  • Shamima Sharmin Shova Department of Paediatrics, Evercare Hospital, Dhaka, Bangladesh
  • Jesmine Akter Mitu Department of Paediatrics and Neonatology, Bangladesh Specialized Hospital, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2349-3291.ijcp20243848

Keywords:

Endocrine, Parathyroid, Transfusion, Thalassemia Major

Abstract

Background: Thalassemia major, a severe form of inherited anemia, requires lifelong blood transfusions to manage the condition and sustain hemoglobin levels. However, these repeated transfusions often lead to iron overload, which can deposit in various organs, including endocrine glands and disrupt normal hormone production. One such affected gland is the parathyroid, responsible for regulating calcium and phosphate balance through parathyroid hormone (PTH) secretion. This study aimed to assess the parathyroid status in children with thalassemia major.

Methods: This case-control analytical study design was considered to assess the parathyroid status in children with thalassemia major. The study was carried out at the Department of Pediatric Hematology and Oncology, Dhaka Medical College Hospital, Dhaka, from July 2012 to June 2013. A total of 40 children with thalassemia major (termed as case) and another 32 normal children (termed as control) were included in the study. Data were analyzed using SPSS (Statistical Package for Social Sciences) version 16.

Results: The study found that children with thalassemia major had significantly lower parathyroid hormone (PTH) levels and higher phosphate levels compared to healthy controls, though calcium levels were similar between groups. Thalassemia patients, primarily receiving blood from professional donors, underwent transfusions for an average of six years, with limited use of chelation therapy (15%). Hypoparathyroidism was significantly more common in thalassemia patients (10%) compared to controls, with 25% also showing hyperphosphatemia. No significant differences were observed in age or sex distribution between the groups.

Conclusions: It can be concluded children with thalassemia possess significantly low serum PTH and high phosphate levels. The serum calcium level does not alter significantly compared to healthy children of similar age and sex. The findings call attention to the critical need for early intervention, regular endocrine screening and diligent chelation therapy in managing thalassemia major.

Metrics

Metrics Loading ...

References

Galanello R, Origa R. Beta-thalassemia. Orphanet journal of rare diseases. 2010;5:1-5.

Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. The Lancet. 2018;391(10116):155-67.

De Sanctis V, Soliman AT, Canatan D, Elsedfy H, Karimi M, Daar S, et al. An ICET-A survey on Hypoparathyroidism in Patients with Thalassaemia Major and Intermedia: A preliminary report. Acta Bio Medica: Atenei Parmensis. 2017;88(4):435.

Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, et al. Multi‐Centre Study of Iron Overload Research Group. Increased prevalence of iron‐overload associated endocrinopathy in thalassemia versus sickle‐cell disease. British journal of hematology. 2006;135(4):574-82.

De Sanctis V, Eleftheriou A, Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatric endocrinology reviews: PER. 2004;1;2:249-55.

Shahriari M, Sadjadian N. Prevalence of endocrine complications in the beta-thalassemia major in the Islamic Republic of Iran. EMHJ-Eastern Mediterranean Health J. 2004;9(1-2):55-60,2003.

Soliman AT, Yassin MA, De Sanctis V. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC. Acta Bio Medica: Atenei Parmensis. 2018;89(2):27.

Borgna PC, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. Annals of the New York Academy of Sciences. 2005;1054(1):40-7.

Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, et al. Bone disease in thalassemia: a frequent and still unresolved problem. Journal of Bone and Mineral Research. 2009;24(3):543-57.

Taher AT, Musallam KM, Cappellini MD. Thalassemia intermedia: an update. Mediterranean J Hematol Infect Diseases. 2009;1(1).

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica. 2007;1;92(5):583-8.

Modell B, Darlison M. Global epidemiology of hemoglobin disorders and derived service indicators. Bulletin of the World Health Organization. 2008;86(6):480-7.

Rund D, Rachmilewitz E. Pathophysiology of α-and β-thalassemia: therapeutic implications. In Seminars in Hematol. 2001;38(4):343-9.

Rostami P, Hatami G, Shirkani A. Endocrine complications in patients with major β-thalassemia. Iranian South Med J. 2011;4;14(4):240-5.

Pennell DJ, Porter JB, Piga A, Lai YR, El‐Beshlawy A. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta-thalassemia major treated with deferasirox or deferoxamine. American J Hematol. 2015;90(2):91-6.

Downloads

Published

2024-12-24

How to Cite

Titas, A., Khasru, A. K. M. A. M., Shova, S. S., & Mitu, J. A. (2024). Endocrine impact of transfusion therapy: parathyroid status in pediatric thalassemia major. International Journal of Contemporary Pediatrics, 12(1), 7–11. https://doi.org/10.18203/2349-3291.ijcp20243848

Issue

Section

Original Research Articles